Dermatologic side effects associated with gefitinib therapy: Clinical experience and management

Clinical Lung Cancer

Volumn 4, Issue 6, 2003, Pages 366-369

  Herbst, Roy S ^a   LoRusso, Patricia M ^b   Purdom, Michele ^a   Ward, Deborah ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Providence Cancer Institute   (United States)

Author keywords

Epidermal growth factor receptor; IDEAL trials; Lung cancer; Rash; Skin; Tyrosine kinase inhibitor

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID DERIVATIVE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; HYDROXYZINE; METHYLPREDNISOLONE; MINOCYCLINE; MONOCLONAL ANTIBODY; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID;

ACNE; ADVANCED CANCER; ARTICLE; BLEPHARITIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; EYE IRRITATION; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; PAPULAR SKIN DISEASE; PUSTULE; SKIN DISEASE; SOLID TUMOR; URINARY TRACT DISEASE; VAGINAL DRYNESS; VAGINAL PRURITUS;

EID: 0038080138     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.016     Document Type: Article

References (20)

1. Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell long cancer. Semin Oncol 2002; 29(suppl 4):37-46.
2. Ranson M. ZD1839 (Iressa™): for more than just non-small cell lung cancer. Oncologist 2002; 7(suppl 4):16-24.
3. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-3825.
4. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
5. Herbst RS, Kies MS. ZD1839 (Iressa™) in non-small cell lung cancer. Oncologist 2OO2; 7 (suppl 4):9-15.
6. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-250.
7. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (suppl 4):2-8.
8. Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000; 60(suppl 1):1-14.
9. Busam KJ, Capodieci P, Metzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-1176.
10. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601.
11. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
12. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13:491-498.
13. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
14. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of inti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-3243.
15. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94:1593-1611.
16. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-124.
17. Hansen LA, Alexander N, Hogan ME, et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997; 150:1959-1975.
18. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10:505-510.
19. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iresse') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21:292a (Abstract #1166).
20. Natale R, Skarin A, Maddox AM, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. presented at: Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL.